Open Access Open Access  Restricted Access Subscription Access

A Comprehensive Overview of Drugs Acting on Anti-Diabetes

Muralinath E., Pooja Devi, Prasanta Chbukdhara, Sanjib Borah, Kalyan C., Archana Jain, Guruprasad M.

Abstract


Diabetes mellitus (DM) is a chronic metabolic disorder manifested by an enhanced blood glucose levels. DM is categorized into type 1 diabetes and Type 2 diabetes. Metformin is an anti-diabetic medication that is related to the biguanide class. Metformin is the first treatment for Type 2 DM because of its efficacy, safety and minimal risk of hypoglycemia. Sulfonyl ureas namely glipizide and glyburide activate insulin secretion from pancreatic beta cells. Meglitinides, like nateglinide and repaglinide also activate insulin secretion, but their action is short - lived compare to sulfonyl ureas. Thiazolidine diones (TZDs) along with pioglitazone and rosiglitazone activate insulin sensitivity particularly in peripheral tissues. They stimulate peroxisome proliferator - activated receptor gamma (PPAR - gamma ) and give rise to an improved glucose utilization and decreased insulin resistance. Dipeptidyl peptidase - 4 (DPP - 4) inhibitors namely saxa gliptin and sita gliptin continue the action of incretin hormones. Inretin activate insulin release and stop glucagon secretion and contribute to glucose control. Sodium - glucose c0-transporter - 2 (SGLT 2) inhibitors along with canagliflozin and dapagliflozin influence kidneys to decrease glucose reabsorption. Alpha-glucosidase inhibitors namely acarbose, decrease digestion and absorption of carbohydrates in the intestine. Finally it is concluded that the management of diabetes is associated with multifaceted approach, often combining lifestyle modifications and pharmacotherapy.


Full Text:

PDF

References


Liu, Z., & Yang, B. (2019). Drug development strategy for type 2 diabetes: Targeting positive energy balances. Current Drug Targets, 20(8), 879-890.

Mellitus, G. D. (2018). ACOG practice bulletin. ACOG: Washington, DC, USA.

Wang, Y., & Perri III, M. (2018). A systematic review of patient-reported satisfaction with oral medication therapy in patients with type 2 diabetes. Value in Health, 21(11), 1346-1353.

Gatwood, J. D., Chisholm-Burns, M., Davis, R., Thomas, F., Potukuchi, P., Hung, A., ... & Kovesdy, C. P. (2018). Impact of pharmacy services on initial clinical outcomes and medication adherence among veterans with uncontrolled diabetes. BMC health services research, 18(1), 1-9.

Hurt, R. T., Mundi, M. S., & Ebbert, J. O. (2018). Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 469-478.

Handelsman, Y., Wyne, K., Cannon, A., Shannon, M., & Schneider, D. (2018). Glycemic efficacy, weight effects, and safety of once-weekly glucagon-like peptide-1 receptor agonists. Journal of Managed Care & Specialty Pharmacy, 24(9-a Suppl), S14-S29.

Costello, R. A., Nicolas, S., & Shivkumar, A. (2018). Sulfonylureas.

Molina-Vega, M., Muñoz-Garach, A., Fernández-García, J. C., & Tinahones, F. J. (2018). The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies. Expert opinion on drug safety, 17(8), 815-824.

Dai, X., Luo, Z. C., Zhai, L., Zhao, W. P., & Huang, F. (2018). Adverse drug events associated with low-dose (10 mg) versus high-dose (25 mg) empagliflozin in patients treated for type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetes Therapy, 9, 753-770.


Refbacks

  • There are currently no refbacks.